Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung07 first-line Dato-DXd plus pembrolizumab with or without platinum chemotherapy in advanced non-squamous NSCLC
NL-OMON60395Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of datopotamab deruxtecan and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2023; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60395.